Genmab · DK0010272202 · GMAB | XCSE | Prime AI Terminal

CUSIP

K3967W102

SEDOL

4595739

CIK

0001434265

genmab.com

LEI: 529900MTJPDPE4MHJ122

New: Infographics X-Lab

BASIC = Free ADVANCED = User Account BUSINESS = Subscription PRIME = Subscription

ENTERPRISE = upon request

PROFILER

BASIC

ADVANCED

BUSINESS

PRIME

AI Insights

Genmab

Click to initiate

ENTERPRISE

5.554,11 S&P · 23,43 Vola-Index · 94.893,71 BTC · 1,13857 EURUSD

Securities Trading Warrants

GlobeNewswire is an important news source that provides investors with company-related information. In particular, it deals with events that may be relevant to the listing of companies or tradable financial instruments. You can access the complete overview of all reports via this link.

Mon, 28.04.2025

Company Announcement

Research & Analysis

Tue, 22.04.2025

Company Announcement

Research & Analysis

Tue, 15.04.2025

Company Announcement

Research & Analysis

Thu, 10.04.2025

Company Announcement

Research & Analysis

Mon, 31.03.2025

Media Release

Research & Analysis

Mon, 31.03.2025

Company Announcement

Research & Analysis

Tue, 25.03.2025

Company Announcement

Research & Analysis

Sat, 22.03.2025

Company Announcement

Research & Analysis

Mon, 17.03.2025

Media Release

COPENHAGEN, Denmark; March 17, 2025

Research & Analysis

Wed, 12.03.2025

Company Announcement

Research & Analysis

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

SMART * AD

P R O D U C T S U G G E S T I O N S

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Page URL

Paste the page URL here

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .

I would like to remain anonymous.

Subject *

e.g. New calculation method for Risk-of-Ruin-Calculator

View/Tool *

This view/tool

Another page/tool

Description of the proposed change/feedback *

The more comprehensible the description, the faster a feasibility check can be carried out.

General feedback on the view/tool/component/content *

Use this feedback text field for general or supplementary information

Would you use the tool and recommend it if necessary? *

Your opinion is valuable. Feel free to share it with us.

Genmab A/S

Newsletter

Genmab A/S

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Genmab A/S Share Capital Reduction

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Transactions in connection with share buy-back program

Genmab Announces Initiation of Share Buy-Back Program

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Newsletter